This article is from the source 'rtcom' and was first published or seen on . It last changed over 40 days ago and won't be checked again for changes.

You can find the current article at its original source at https://www.rt.com/news/514512-switzerland-astrazeneca-covid-vaccine-data/

The article has changed 3 times. There is an RSS feed of changes available.

Version 1 Version 2
Switzerland delays approval of AstraZeneca and Johnson & Johnson Covid-19 vaccines due to 'insufficient data' Switzerland delays approval of AstraZeneca and Johnson & Johnson Covid-19 vaccines due to 'insufficient data'
(about 1 month later)
The Swiss drugs regulator will delay its approval of the two Covid-19 vaccines developed by AstraZeneca and Johnson & Johnson until it receives more data on their efficacy at preventing the virus, the agency said on Wednesday.The Swiss drugs regulator will delay its approval of the two Covid-19 vaccines developed by AstraZeneca and Johnson & Johnson until it receives more data on their efficacy at preventing the virus, the agency said on Wednesday.
Swissmedic, the country's regulator, said the current data for the AstraZeneca jab is "not yet sufficient for approval" and it has now called for more information on the vaccine's "safety, effectiveness and quality."Swissmedic, the country's regulator, said the current data for the AstraZeneca jab is "not yet sufficient for approval" and it has now called for more information on the vaccine's "safety, effectiveness and quality."
Specifically, the Swiss agency has asked for efficacy data from the ongoing phase III trial being carried out in North and South America, where the AstraZeneca vaccine is being tested on 30,000 people.Specifically, the Swiss agency has asked for efficacy data from the ongoing phase III trial being carried out in North and South America, where the AstraZeneca vaccine is being tested on 30,000 people.
Swissmedic is currently conducting "rolling reviews" of both the AstraZeneca and Johnson & Johnson vaccines, meaning in theory that a quick decision can be made once the relevant data is available and reviewed.Swissmedic is currently conducting "rolling reviews" of both the AstraZeneca and Johnson & Johnson vaccines, meaning in theory that a quick decision can be made once the relevant data is available and reviewed.
"When the AstraZeneca and Johnson & Johnson vaccines can be approved depends on the quality of the missing documents. A prognosis is difficult," Swissmedic said in a statement."When the AstraZeneca and Johnson & Johnson vaccines can be approved depends on the quality of the missing documents. A prognosis is difficult," Swissmedic said in a statement.
The AstraZeneca vaccine, which was developed with the University of Oxford, has already been approved by drug regulators in the UK and the EU, and is now being rolled out.The AstraZeneca vaccine, which was developed with the University of Oxford, has already been approved by drug regulators in the UK and the EU, and is now being rolled out.
The US and some European nations have been cautious about the jab however, after a dosing mistake during clinical trials saw some participants under the age of 55 accidentally given half doses of the vaccine, followed by full second doses.The US and some European nations have been cautious about the jab however, after a dosing mistake during clinical trials saw some participants under the age of 55 accidentally given half doses of the vaccine, followed by full second doses.
But on Tuesday hopes for the vaccine's efficacy were buoyed, as researchers at Oxford said the jab was shown to be 76 percent effective 12 weeks after a first dose was given, according to a preprint study published in The Lancet.But on Tuesday hopes for the vaccine's efficacy were buoyed, as researchers at Oxford said the jab was shown to be 76 percent effective 12 weeks after a first dose was given, according to a preprint study published in The Lancet.
Switzerland has already approved the Covid-19 vaccines made by Pfizer-BioNTech and Moderna.Switzerland has already approved the Covid-19 vaccines made by Pfizer-BioNTech and Moderna.
The Swiss government has also signed agreements for 5.3 million doses of the AstraZeneca jab, six million doses of the Novavax jab, and five million doses of a vaccine by Curevac and GlaxoSmithKline, which is still in the pipeline.The Swiss government has also signed agreements for 5.3 million doses of the AstraZeneca jab, six million doses of the Novavax jab, and five million doses of a vaccine by Curevac and GlaxoSmithKline, which is still in the pipeline.
Like this story? Share it with a friend!Like this story? Share it with a friend!
Dear readers and commenters,
We have implemented a new engine for our comment section. We hope the transition goes smoothly for all of you. Unfortunately, the comments made before the change have been lost due to a technical problem. We are working on restoring them, and hoping to see you fill up the comment section with new ones. You should still be able to log in to comment using your social-media profiles, but if you signed up under an RT profile before, you are invited to create a new profile with the new commenting system.
Sorry for the inconvenience, and looking forward to your future comments,
RT Team.